Aveo Oncology gets initial warning from Nasdaq that it could be delisted
December 30, 2014 at 11:00 AM EST
A Cambridge biotech struggling to claw its way back after a devastating FDA rejection in 2013, Aveo Oncology has been notified that its stock stock price is too low to remain on the Nasdaq Global Market...